Characterization of chronic kidney disease in rats treated with lithium

OSSANI G.P; UCEDA A.M; REPETTO M.G.; LAGO N.R.; ZOTTA E.; MARTINO D.J.

Congreso; Reunión anual de Sociedades Biocientíficas,; 2019

Lithium (Li) is the drug of choice for long-term prophylactic treatment of bipolar disorder. Chronic kidney disease is one of the complications of prolonged use of Li, which may be more frequent than previously thought. The aim of this study was to evaluate renal damage in rats treated with Li for 3 and 6 months. Rats were divided into 4 groups (G): control (C) fed ad libitum standard diet or experimental (E) fed the same diet containing 60 mmol Li/kg diet. C and E rats were sacrificed after 3 or 6 months of experiment (3 or 6). Lithemia, serum creatinine (SC), Clearance of creatinine (CrCl) and fractional excretion of sodium (FENa) were measured. Kidney samples were processed for: histopathology; oxidative stress (TBARs); immunohistochemistry (Aquaporin-2; AQP2). Lithemia (mmol/L) reached therapeutic values in both EG (E3=0.69±0.14 and E6=0.63±0.13). SC (mg/dl) was higher in both EG (C3=0.37±0.05 vs E3=0.46±0.11; t=-2.22, p=0.043; C6=0.36±0.04 vs E6=0.46±0.09; Z=-2,26, p=0.024). CrCl (mL/min) was lower in both EG (C3=2.84±0.43 vs E3=1.33±0.55; t=6.13, p